Introduction
Fibrosis is becoming increasingly recognized as a major cause of morbidity and mortality in modern populations, yet still, no targeted antifibrotic therapies have been approved for most fibrotic disorders. Through intensive research over the last decade, our understanding of the underlying pathogenesis of fibrotic diseases has improved. We now recognize fibrosis to be the consequence of persistent tissue repair responses, which, in contrast to normal wound healing, have not been effectively terminated by the body.
Profibrotic mediators released from infiltrating leukocytes, activated endothelial cells, and degranulated platelets may be the predominant drivers of fibroblast activation and collagen release during the early stages of fibrosis, whereas endogenous activation of fibroblasts due to epigenetic modifications and biomechanical or physical factors, such as hypoxia and stiffening of the extracellular matrix (ECM), may play a pivotal role in disease progression during the later stages. We discuss herein novel insights into the pathogenesis of fibrotic diseases, using systemic sclerosis (SSc) as an example of a multisystem idiopathic disorder. We set a strong translational focus and mainly discuss approaches with very high potential for rapid transfer from bench to bedside. We also highlight the molecular basis of ongoing clinical trials in SSc and provide an outlook for upcoming trials.
Responses to tissue injury
Fibrosis is defined as the excessive deposition of fibrous connective tissue in an organ or tissue initiated by tissue repair programs in response to injury. The accumulation of ECM often disrupts the physiologic architecture and can lead to organ malfunction. Normal wound healing and fibrotic diseases share many similarities. In both cases, an initial injury initiates a series of reparative processes in damaged tissues to restore organ integrity. These processes involve leukocyte activation and infiltration and culminate in the accumulation of myofibroblasts, which release ECM and cause the damaged tissue to contract ( Figure 1 ). Myofibroblasts are a heterogeneous population of cells characterized by the expression of contractile proteins and a high capacity for ECM synthesis. Myofibroblasts may be primarily derived from transdifferentiation of resident fibroblasts and pericytes, but other tissueresident cell types, such as epithelial cells, endothelial cells, smooth muscle cells, and adipocytes as well as bone marrow-derived fibrocytes and other precursor and progenitor cell populations, may also contribute to the pool of myofibroblasts (Figure 1) .
Under normal conditions, the usual reparative responses are terminated after sufficient repair of the damage, whereas in the presence of a fibrotic disease, tissue remodeling and fibroblast activation persist. Fibrotic diseases may thus be considered to be exaggerated and prolonged wound-healing responses (1) . As a consequence, impaired termination may also drive the progression of fibrotic diseases in addition to pathologic activation of tissue repair responses (Figure 1 ).
Fibrotic diseases can affect virtually every organ system. In addition to classic fibrotic diseases, tissue fibrosis is a common outcome of almost all chronic diseases. Fibrotic tissue responses can make an important contribution to morbidity or disease progression, even in diseases not commonly associated with fibrosis. For example, fibrotic tissue responses mediate vascular remodeling in atherosclerosis, myocardial remodeling in chronic heart failure, and small-airway remodeling in chronic obstructive pulmonary disease or in asthma. Fibrotic tissue remodeling also influences tumor invasion and metastasis. Indeed, it has been estimated that up to 45% of all deaths in the developed world can be attributed to some type of chronic fibroproliferative disease (2) . In general, the global incidence of fibrosis and the associated health care burden are increasing, and fibrosis is therefore becoming more recognized as one of today's major health care challenges (2,3). As there are only a few antifibrotic therapies and even fewer targeted approaches, there remains a major need for continued intensive research and active drug discovery.
Contrary to the long-held perception that fibrosis is permanent, multiple lines of evidence indicate considerable plasticity of fibrotic tissues. Although this plasticity varies between different organs and individual diseases, the accumulation of ECM is not irreversible, but can regress, when major effector cells, such as myofibroblasts, are eliminated and the balance of matrix synthesis and degradation is shifted toward degradation (3).
While originally investigated as different disease entities, it is now clear that several common pathways orchestrate fibrotic tissue responses of all organs (4). This perception, together with the identification and characterization of several key regulators of fibrosis, stimulated increasing interest of pharmaceutical companies in the development of targeted antifibrotic therapies. Those efforts led to the approval of the first two antifibrotic drugs (nintedanib and pirfenidone, both for treatment of idiopathic pulmonary fibrosis), a rapidly growing number of clinical trials of antifibrotic drugs, and numerous promising small molecules that are in the early stages of clinical development for use as treatments. The most advanced approaches in the context of SSc are reviewed here.
Vascular damage and platelet degranulation
Vascular alterations in fibrotic diseases are particularly prominent in SSc and are associated with profound imbalances between proangiogenic and antiangiogenic mediators, as well as between vasoconstrictive and vasodilative factors. First, vascular changes occur early in the pathogenesis of SSc and precede fibrotic manifestations in humans and in murine models (5) . The exposure of subendothelial ECM and the reduced blood flow rates in damaged vessels lead to activation and degranulation of platelets in SSc (6) . Platelet granules contain large amounts of serotonin, or 5-hydroxytryptamine (5-HT). More than 90% of the serotonin in the human body is stored in 
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DISTLER ET AL platelets. Consistent with the increased activation of platelets in patients with SSc, blood levels of 5-HT are elevated. Inhibition of platelet activation by high doses of clopidogrel was shown to ameliorate the fibrosis that occurs in tight skin (TSK) mice as well as that experimentally induced by bleomycin (7) . Antiplatelet therapy has also been shown to ameliorate fibrosis of the heart, aortic valve, kidneys, and liver (8, 9) . Further studies demonstrated that mice deficient in tryptophan hydroxylase 1, which is characterized by very low platelet levels of 5-HT, are also protected from the development of experimental fibrosis (7) . It has been shown that 5-HT directly stimulates the release of collagen in cultured human fibroblasts, human mesangial cells, and murine cardiac fibroblasts. Pharmacologic and genetic analyses have demonstrated that these stimulatory effects on fibroblasts are mediated by 5-HT receptor 2B (5-HT 2B ). Mice deficient in 5-HT 2B are protected from the development of experimental skin fibrosis (7) . Treatment with the nonselective 5-HT 2 inhibitors terguride and cyproheptadine (both of which are in clinical use), as well as with the selective 5-HT 2B inhibitor SB204741, also exerted potent antifibrotic effects. Selective inhibition of 5-HT 2B also showed therapeutic potential in mouse models of liver fibrosis (10) .
The effects of terguride in SSc patients were evaluated in a small, nonblinded proof-of-concept trial. SSc patients treated with terguride were found to have lower modified Rodnan skin thickness scores (MRSS) as compared to untreated controls. Moreover, dermal thickness, myofibroblasts counts, and levels of messenger RNA (mRNA) for type I collagen, transforming growth factor b1 (TGFb1), and the recently proposed 4-gene biomarker set (11) were reduced following treatment with terguride (12) . These results prompted the initiation of a confirmatory phase III randomized, placebo-controlled clinical trial of terguride in patients with early, diffuse cutaneous SSc (dcSSc), which was set to start recruitment in 2017.
However, 5-HT is not the only profibrotic mediator stored in platelets. Platelet granules contain an array of other profibrotic mediators, including growth factors, such as TGFb, platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF), and bioactive lipids, such as lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P) receptor (13) . Several of these mediators and ongoing clinical programs targeting them are discussed in more detail below. The release of a plethora of profibrotic mediators from activated platelets at sites of vascular damage thus provides a direct pathophysiologic link between vascular injury and tissue fibrosis.
Activation of the coagulation cascade upon injury of the tissue may also promote fibrosis in SSc as well as in other fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) (14) . Thrombin enhances the proliferative effects of fibrinogen on fibroblasts, induces the expression of profibrotic growth factors, stimulates the release of ECM proteins, and promotes the transdifferentiation of resting fibroblasts into myofibroblasts. Thrombin levels are elevated in patients with SSc, and findings suggest that patients are in a hypercoagulable state (15) . Direct thrombin inhibitors, such as dabigatran, were shown to reduce the activated phenotype of SSc fibroblasts and demonstrated antifibrotic effects in a model of bleomycin-induced lung fibrosis in both the preventive and therapeutic settings (16) . Further, thromboxane A 2 (TXA 2 ) and its receptor have also been implicated in impaired angiogenesis in SSc.
Patients have elevated circulating levels of 8-isoprostane, which has been shown to activate the TXA 2 receptor (17) and increase the expression of thromboxane synthase in leukocytes, resulting in increased serum levels of TXA 2 (18) . Anticoagulation therapy has been a topic of controversy in patients with SSc-associated pulmonary arterial hypertension (PAH) and does not seem to offer any benefit over other available therapies for PAH (19) .
Leukocyte activation and cytokine release
A characteristic feature of SSc is the presence of perivascular inflammatory infiltrates associated with regions of activated fibroblasts and matrix remodeling. Inflammatory infiltrates are seen early in the course of SSc (5) and are thought to induce fibroblast activation and initiate tissue repair responses. While research initially focused mainly on adaptive immune responses, accumulating evidence points to a key role of innate immune responses in fibrotic diseases such as SSc, and Toll-like receptors and innate lymphocyte cells have gained increasing interest (20, 21) . The central role of aberrant immune activation in the fibrosis of SSc is emphasized by the success of highdose immunosuppression with subsequent autologous stem cell transplantation (22) . Although a plethora of inflammatory mediators might have the potential for targeted intervention, we focus here on candidates that are in ongoing clinical trials. A list of other potential targets is available upon request from the corresponding author.
Interleukin-6 (IL-6) is a central regulator of acutephase responses and plays a key role in the transition from innate to acquired immunity. IL-6 signals are transduced into the nucleus by IL-6 receptor a (IL-6Ra) and gp130 via JAK/STAT (23) . Among its pleiotropic effects, IL-6 has been implicated in fibroblast activation and collagen release. Serum levels of IL-6 are elevated in SSc patients and correlate positively with skin thickening (24) . Increased amounts of IL-6 are also detected in the lesional skin of SSc patients (25) . Although IL-6Ra is not expressed on the surface of dermal fibroblasts, gp130 is expressed, and IL-6 activates fibroblasts via trans-signaling through an association between soluble IL-6R, IL-6, and gp130 (26) . Genetic deletion of the IL-6 gene in mice or treatment with anti-mouse IL-6R antibodies was shown to attenuate bleomycin-induced fibrosis (27) . A phase II randomized, double-blind, placebo-controlled trial of subcutaneous tocilizumab in patients with early dcSSc and with a large number of patients with inflammatory features failed to meet its primary end point but showed a clear trend toward improvement in the MRSS. Moreover, several secondary and exploratory end points improved in a statistically significant manner (28, 29) . Those results promoted initiation of a phase III follow-up trial of tocilizumab in SSc, which is currently recruiting participants (ClinicalTrials.gov identifier: NCT02453256).
A central paradigm of fibrotic diseases is a Th2 bias in T cell differentiation. High levels of Th2 cytokines, such as IL-4 and IL-13, in serum from patients with SSc have been reported (30) . IL-13-targeting therapies were shown to attenuate experimental pulmonary and hepatic fibrosis (31, 32) . However, a phase II doubleblind, placebo-controlled trial of an anti-IL-13 antibody (QAX576; Novartis) in patients with IPF was closed preterm in 2013. Other approaches to targeting Th2 differentiation or cytokines are still in preclinical or earlier clinical development.
B cells are part of the inflammatory infiltrates in fibrotic skin, and the presence of autoantibodies in the sera of patients with fibrotic diseases suggests that B cells are involved in the pathogenesis of fibrosis (33, 34) . Chronically abnormal B cell activity might contribute to an imbalance of cytokines, which promotes Th2 predominance and fibrosis. In addition, certain autoantibodies, such as those against PDGF (35) , endothelin, and angiotensin receptors (36) , might directly stimulate the release of collagen from fibroblasts. The role of B cells in the pathogenesis of SSc is further supported by studies demonstrating that a deficiency of CD19 protects TSK mice as well as mice injected with bleomycin from developing fibrosis (37) . A retrospective analysis of the European League Against Rheumatism Scleroderma Trials and Research cohort identified greater improvement in the MRSS and better forced vital capacity (FVC) in SSc patients treated with the B cell-depleting CD20 antibody rituximab as compared to controls (matched SSc patients not taking rituximab) (38) . Prospective randomized controlled trials are needed to confirm these encouraging results. Two trials with rituximab in SSc are currently ongoing. One is a phase II randomized, double-blind, placebo-controlled trial recruiting patients with SSc-associated PAH (Clinical Trials.gov identifier: NCT01086540), and the other is a trial in patients with SSc-related polyarthritis (ClinicalTrials.gov identifier: NCT01748084).
Another approach to targeting inflammation in SSc that is currently being evaluated in a clinical trial is inhibition of the cannabinoid receptor CB 2 . Exogenous as well as endogenous cannabinoids transmit their signals by 2 different cell surface receptors, CB 1 and CB 2 , both of which are heterotrimeric GTP binding protein-coupled receptors. Cannabinoids can modulate fibrotic tissue responses via CB 1 and CB 2 . While CB 2 mainly regulates leukocyte infiltration, CB 1 may also affect resident cells, such as fibroblasts (39, 40) . Besides skin fibrosis, cannabinoids also contribute to the pathogenesis of liver fibrosis (41) . Potential therapeutic effects of targeting CB 2 with the synthetic cannabinoid-mimetic JBT-101 in SSc are currently under investigation in a phase II clinical trial in patients with early dcSSc (ClinicalTrials.gov identifier: NCT02465437).
Transforming growth factor b signaling
TGFb is a master regulator of mesenchymal tissue responses. Although TGFb1 is the most abundantly expressed isoform, the other isoforms of TGFb (TGFb2 and TGFb3) are also up-regulated in SSc. In addition to its regulatory activity at the transcription level, the availability of bioactive TGFb is also modulated by cleavage of latent TGFb and by sequestration in the ECM (for further details on TGFb signaling in SSc, see recent reviews published elsewhere, such as that in ref. 42 ). Activation of TGFb signaling, e.g., by fibroblast-specific overexpression of a constitutively active TGFb receptor type I (TGFbRI), is sufficient to induce fibrosis (43) . The expression of a subset of TGFbregulated genes correlates with the MRSS and with myofibroblast counts (11) . Numerous preclinical studies have further demonstrated that inhibition of TGFb signaling exerts potent antifibrotic effects in various animal models across different organs (42) . Nevertheless, the first attempt to inhibit TGFb signaling in SSc using recombinant TGFb1-neutralizing antibodies (CAT-192) failed to show efficacy in a placebo-controlled trial (44) . The results of that trial, however, did not provide evidence against inhibition of TGFb signaling in SSc, since CAT-192 had only an insufficient affinity for TGFb1 in vivo.
A more recent study without controls evaluated the effect of a high-affinity neutralizing antibody that targets all 3 TGFb isoforms (fresolimumab) in SSc. The investigators reported a decrease in the MRSS early after the first infusion of fresolimumab. This decrease was accompanied by reduced levels of mRNA for several TGFb-regulated 260 DISTLER ET AL genes and decreased myofibroblast counts in fibrotic skin (45) . However, some studies noted a high number of keratoacanthomas at multiple sites in patients treated with fresolimumab (46) . Mechanistically, the appearance of keratoacanthomas can be explained by the fact that TGFb inhibits the proliferation of keratinocytes. While potent, systemic long-term inhibition of all TGFb isoforms or direct targeting of the TGFb receptors may thus be prohibited by safety concerns, several strategies have been developed to target downstream mediators of TGFb signaling.
A recently identified intracellular downstream mediator of TGFb signaling with translational potential is soluble guanylate cyclase (sGC). Soluble GC catalyzes the production of cyclic GMP (cGMP) upon the binding of nitric oxide. Increasing levels of cGMP inhibit TGFb-dependent fibroblast activation (47) . These sGC stimulators do not interfere with canonical TGFb signaling, but may exert their antifibrotic effects by inhibiting TGFb-dependent activation of ERK (48) . In addition, sGC stimulators demonstrated antifibrotic effects in various experimental mouse models of SSc (47, 49) . The sGC stimulator riociguat was approved in 2015 for the treatment of PAH. Riociguat is currently being evaluated in a large randomized placebo-controlled study in patients with early dcSSc.
Nuclear receptors are a superfamily of transcription regulators that are becoming increasingly recognized as regulators of mesenchymal tissue responses. Several nuclear receptors have recently been suggested to be potential targets for antifibrotic therapies (50) (51) (52) (53) (54) . The most advanced are the clinical programs with agonists of peroxisome proliferator-activated receptors (PPARs). PPARg in particular has been linked to fibroblast activation in SSc. The expression of PPARg is decreased in fibrotic tissues from SSc patients (55) . PPARg agonists, such as thiazolidinediones, inhibit TGFb-induced myofibroblast differentiation and collagen release in vitro by interfering with the recruitment of the coactivator p300 to Smad-binding sites (56) . Thiazolidinediones also ameliorate bleomycin-induced skin fibrosis. However, selective PPARg agonists have been associated with elevated levels of low-density lipoprotein (LDL), and rosiglitazone was suspended from use in Europe because of an increased risk of heart attack and stroke. Combined activation of all members of the PPAR family may overcome the safety limitations of thiazolidinediones. The pan-PPAR agonist IVA337 was shown not to increase the levels of LDL and demonstrated potent antifibrotic effects in several preclinical models of SSc (57) . A phase II randomized, placebocontrolled trial of IVA337 in dcSSc was started in October 2015.
Vitamin D receptor (VDR) also regulates fibrotic tissue responses and has potential for rapid transfer from bench to bedside. Decreased levels of vitamin D have been observed in various autoimmune diseases including SSc (58) . In addition to a lack of vitamin D, the expression of VDR is down-regulated in affected skin of SSc patients (51) . VDR directly regulates the sensitivity of fibroblasts to the profibrotic effects of TGFb. While knockdown of VDR was shown to enhance TGFb-induced myofibroblast differentiation and collagen release, synthetic VDR agonists reduced the stimulatory effects of TGFb. Mechanistically, VDR binds to phosphorylated Smad3 to inhibit its transcriptional activation. Preventive and therapeutic treatment with VDR agonists ameliorated bleomycin-induced as well as TGFbRI-induced fibrosis. Moreover, VDR-null mice spontaneously develop liver fibrosis, and it has been shown that vitamin D analogs prevent carbon tetrachlorideinduced liver fibrosis as well as renal fibrosis induced by unilateral ureteral obstruction (59, 60) . Numerous compounds that modulate VDR signaling are currently in clinical use and are available for clinical trials.
Bioactive lipid mediators, such as LPA and S1P, have also been identified as important regulators of TGFb signaling in fibrotic diseases (61, 62) . Levels of LPA are elevated in the serum of SSc patients (63) . LPA is chemotactic for fibroblasts, induces the expression of TGFb and connective tissue growth factor, and promotes myofibroblast differentiation. Knockout of the LPA 1 receptor or treatment with an LPA 1 antagonist was shown to protect mice from bleomycin-induced pulmonary and dermal fibrosis and to ameliorate fibrosis in TSK mice (64) . An orally available LPA 1 receptor antagonist (SAR100842) was evaluated in a phase IIa clinical trial in patients with dcSSc. Although no significant differences in the MRSS were observed between the SAR100842 and placebo treatment groups, effective target engagement was demonstrated, and the levels of 2 potential biomarkers of skin fibrosis, cartilage oligomeric matrix protein and thrombospondin 1, were reduced (65) . Clinical trials of LPA antagonists (either LPA 1 or LPA 1-3 ) in SSc and other fibrotic diseases are currently under consideration.
Pirfenidone has been approved for the treatment of IPF based on the demonstration of a reduced loss of FVC as compared to placebo in 2 of 3 clinical trials. Although the molecular mechanisms underlying the antifibrotic effects of pirfenidone are not completely understood, it is thought to work predominantly by modulating TGFb and tumor necrosis factor signaling. An open-label phase II trial of pirfenidone in SSc-related interstitial lung disease (ILD) was recently completed (66) . Although exploratory disease outcomes remained largely unchanged, a follow-up trial in patients with SSc-related ILD is planned (Clinical Trials.gov identifier: NCT01933334).
Reactive oxygen species produced by the NADPH oxidase (NOX) system are believed to play important roles in tissue injury and fibrosis (67) . Several NOX isoforms have been identified, with levels of NOX-2 and NOX-4 being found to be elevated in SSc patients and to be the most relevant to fibrosis (68) . Both a deficiency of NOX-4 and inhibition of NOX-4 by targeting with a small molecule (GKT137831) have been shown to reduce fibroblast activation in the lung and liver (69, 70) . Safety trials of the selective NOX inhibitor GKT137831 have been completed (ClinicalTrials.gov identifier: NCT02010242), and the molecule has recently been granted orphan drug status for development as a treatment in SSc.
Integrins, mechanical forces, and extracellular matrix
The composition of the ECM, mechanical forces, and the stiffness of the ECM alter the activation and bioavailability of several growth factors, including TGFb (71) . Enhanced activation of latent TGFb is thought to contribute to aberrant TGFb signaling in fibrotic diseases. Several members of the integrin family of transmembrane receptors may contribute to enhanced activation of latent TGFb in SSc. The av integrins are recognized to be potent activators of TGFb1 and TGFb3. Deletion of the ITGB6 gene, which encodes avb6 integrin and is up-regulated in patients with SSc-related ILD, was shown in a mouse study to lead to resistance to bleomycin-induced pulmonary fibrosis (42, 72) . Moreover, avb8 integrin may play important roles in TGFb activation and fibrotic tissue remodeling (73) . Furthermore, ECM proteins, such as fibronectin and thrombospondin 1, can activate latent TGFb.
Fibroblasts not only synthesize and remodel the ECM, but in turn, the composition and mechanical properties of the ECM influence fibroblast activation. Fibroblasts sense the stiffness of the ECM via integrins (74) . It has been shown that b1 integrin is overexpressed on SSc fibroblasts. Mice with fibroblast-specific loss of b1 integrin are protected from developing bleomycin-induced fibrosis (75) . Treatment with blocking antibodies against b1 integrin was shown to ameliorate fibrosis in a transgenic mouse model harboring a mutation in the fibrillin gene associated with stiff skin syndrome (76) . These findings stimulated the initiation of clinical trials of antibodies that block b1 integrin in IPF, and studies in other conditions such as SSc are currently under consideration. Besides the targeting of individual integrin subunits, inhibitors that target selective heterodimers might be a promising and more specific approach, as was recently shown with a small-molecule avb1 integrin inhibitor (77) .
Collagen fibrils are crosslinked during collagen maturation to enhance their stability. The crosslinking of type I collagens is mediated by lysyl oxidase (LOX) and LOX-like 1-4 (LOXL-1-4), which are overexpressed in SSc and in other fibrotic diseases (78) . Targeting LOXL-2 with inhibitory antibodies was shown to reduce TGFb signaling, inhibit collagen release, and ameliorate experimental liver and lung fibrosis in animal models (79) . Although we are not aware of clinical trials in patients with SSc, a humanized monoclonal anti-LOXL-2 antibody (GS-6624) is currently in phase II clinical trials for IPF and hepatic fibrosis.
Several extracellular proteins are cleaved to release fragments known as matrikines that exert biologic activity. The noncollagenous carboxy-terminal domain of type XVIII collagen is cleaved by cathepsin L to release endostatin, a protein known for its antiangiogenic activity (80) . The antifibrotic activity of endostatin has recently emerged as one of its important functions. A peptide corresponding to the carboxy-terminal region of endostatin was shown to exert antifibrotic activity in multiple preclinical models of skin and lung fibrosis (81) . The mechanism of action of the peptide included a reduction in the levels of the Egr-1 transcription factor, as well as a reduction in ECM components and the crosslinking enzyme LOX (82) . Recombinant endostatin was shown to attenuate hepatic fibrosis induced by carbon tetrachloride, to improve interstitial fibrosis in a mouse model of renal injury, to reduce bleomycin-induced lung fibrosis, and to inhibit hypertrophic scarring (83) (84) (85) . It is worth noting that conflicting data have been reported for its use in a rat model of myocardial infarction (86) .
Stem cell pathways
Accumulating evidence has demonstrated that morphogenic pathways, including Wnt, hedgehog, Notch, and Hippo signaling, also play important roles in fibrotic diseases. The preclinical evidence for targeting Wnt, hedgehog, and Notch has recently been reviewed in detail elsewhere (87) (88) (89) . These studies may have direct translational implications, as all pathways are treatable with drugs, and several inhibitors are either under advanced clinical development or are already in clinical use (list is available upon request from the corresponding author). While the targeting of Notch signaling by inhibition of the g-secretase complex may be limited by gastrointestinal toxicity caused by a shift in differentiation from enterocytes in the intestinal crypts to mucin-secreting goblet cells (90) , the first clinical trials suggest that targeting of canonical Wnt signaling with tankyrase and porcupine inhibitors is better tolerated. Targeting of hedgehog signaling with inhibitors of smoothened also showed a favorable adverse event profile and vismodegib has already been approved 262 DISTLER ET AL for the treatment of basal cell carcinoma. Despite those encouraging results, however, potential toxicity of inhibitors of hedgehog, Notch, and in particular, Wnt signaling to the stem cell compartment remains a major safety concern for long-term application. A potential approach to overcoming safety concerns with systemic application is topical application. This approach is currently being investigated for C-82, a small molecule that interferes with the interaction of b-catenin with the coactivator CREB binding protein (CinicalTrials.gov ID NCT02349009).
Epigenetics
Epigenetics refers to all heritable changes in phenotype or in gene expression states that are not encoded by changes in the nucleotide sequence of the DNA. Epigenetic modifications are thought to contribute to the basic activation of SSc fibroblasts under cell culture conditions and may contribute to the persistent tissue repair responses in fibrotic diseases. Several aberrant epigenetic modifications have been implicated in the pathogenesis of SSc and other fibrotic diseases (91) (92) (93) .
The most extensively studied target of aberrant DNA methylation in SSc is Fli-1, a member of the Ets family of transcription factors. Fli-1 is silenced due to increased promoter methylation in SSc fibroblasts (94) . Knockdown of the Fli-1 gene in cultured fibroblasts stimulates the release of collagen. Moreover, targeted heterozygous inactivation of Fli-1 together with Kruppel-like factor 5 (KLF5), another transcription factor that is epigenetically suppressed in SSc dermal fibroblasts, in mice (Fli-1
Klf5
1/-mice) was shown to reproduce the 3 cardinal pathologic features of SSc: immune abnormalities, vasculopathy, and fibrosis (95) . Other genes down-regulated Figure 2 . Pathways and network targets of tissue fibrosis in systemic sclerosis. The common events in tissue remodeling and excessive scarring that lead to persistent fibrosis can be targeted at selective points in the fibrogenic process. Damage and chronic inflammation encourage the recruitment of progenitor populations into lesional tissue and stimulate the differentiation of resident fibroblasts. Activated myofibroblasts contribute to the production, deposition, and modification of the extracellular matrix (ECM). Abnormal ECM composition and structure enhances cell-matrix interactions, which in the context of inflammation and a profibrotic environment, impede scar resolution, promoting tissue fibrosis and persistence, which culminate in compromised organ function. RXFP-1 5 relaxin/insulin-like family peptide receptor 1; PAI 5 plasminogen activator inhibitor; PAR 5 protease-activated receptor; ALK-5 5 activin receptor-like kinase 5; ATX 5 autotaxin; S1PR 5 sphingosine 1-phosphate receptor; TNK-1/2 5 tankyrase 1/2; C proteinase 5 procollagen C-proteinase (same as bone morphogenetic protein 1); P4H 5 prolyl 4-hydroxylase; FAK 5 focal adhesion kinase; ROCK-1/2 5 Rho-associated protein kinase 1/2; LOX 5 lysyl oxidase; LOXL2 5 lysyl oxidase-like 2; TGM-2 5 transglutaminase 2.
by DNA methylation are suppressors of cytokine signaling 3 and endogenous Wnt antagonists, such as Dkk-1 and secreted Frizzled-related protein 1 (96) . Pharmacologic inhibition of DNA methylation with 5-aza-2 0 -deoxycytidine normalized the expression levels of these antifibrotic genes, inhibited collagen release by SSc fibroblasts, and ameliorated fibrosis in several mouse models of SSc (96) . Moreover, inhibitors of DNA methyltransferases also demonstrated antifibrotic effects in murine models of other fibrotic diseases (97) .
Polypharmacologic approaches
Polypharmacologic therapy describes the simultaneous inhibition of several pathologically relevant targets by the use of a single drug. Given the complex pathogenesis of fibrotic diseases, a single pathway intervention is unlikely to be curative, and polypharmacologic interventions are considered to be promising antifibrotic approaches despite the theoretically increased risk of adverse effects. The most relevant example to date is the multiple tyrosine kinase inhibitor nintedanib. Nintedanib has been shown in two phase III replication trials (INPULSIS-1 and INPULSIS-2) to slow the loss of FVC in patients with IPF and was approved for the treatment of IPF in 2014/2015 (98) . Nintedanib blocks PDGF receptors a and b, FGF receptors 1, 2, and 3, VEGF receptors 1, 2, and 3, and the Src family kinases Src, Lyn, and Lck by blocking the intracellular ATP-binding pocket (99) . Several of the molecular targets of nintedanib, such as the PDGF, VEGF, and Src signaling cascades, have also been linked to the pathogenesis of fibrosis in SSc (100) (101) (102) (103) (104) . Pathologic activation of PDGF receptors or VEGF receptors is sufficient to induce fibrosis in mice (102, 103) , and Src kinases serve as downstream mediators of several profibrotic growth factors, including TGFb (104) . Nintedanib thus offers an option for the combined inhibition of several profibrotic pathways. Indeed, nintedanib inhibited proliferation, migration, myofibroblast differentiation, and collagen release from cultured fibroblasts and showed antifibrotic effects in various in vivo models of SSc (105) . The efficacy of nintedanib in SSc-related ILD is currently being evaluated in a phase III clinical trial (ClinicalTrials.gov identifier: NCT02597933).
Conclusions
Identification of potential targets is the initial step in the development of antifibrotic therapies. Increasing the framework for understanding the pathogenesis of fibrotic diseases will provide further insights and offer opportunities for the development of effective antifibrotic treatment strategies. Indeed, our understanding of the molecular pathogenesis of fibrotic diseases is increasing, and the list of potential molecular targets for the treatment of fibrosis is growing (Figure 2 ) (further information is available upon request from the corresponding author). Several of those studies have direct translational implications, since the mediators identified can be targeted pharmacologically with available drugs. Indeed, some of these studies have already been transferred from bench to bedside, with clinical trials that are either in preparation or ongoing ( Table 1 ). The diversity of the available strategies raises hope for the beginning of a new era of diseasespecific treatment strategies for fibrotic diseases. 
